Phenylketonuria Treatment Market Driven by Growing Awareness Programs
In 2024, the global phenylketonuria (PKU) treatment market was valued at USD 518.7 million, and it is expected to grow to USD 851.0 million by 2030, representing a compound annual growth rate (CAGR) of 9.4% during the period from 2025 to 2030. Growth is being driven by an increased prevalence of PKU along with rising healthcare spending, which is improving access to treatments. Key Market Trends & Insights In 2024, North America accounted for the largest share of the PKU treatment market at 52.1%, making it the dominant region. The Asia Pacific region is projected to register the fastest regional growth, with a CAGR of 10.8% over the forecast period. When considering types of drug treatments, Palynziq held the majority share in 2024—about 67.9%—and is expected to grow at a noteworthy CAGR through 2030. Looking at how drugs are administered, the parenteral administration segment not only held the largest market share in 2024 but is also forecast to expand at the fastest...